{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:28:23Z","timestamp":1790832503930,"version":"4.1.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100010293","name":"Seattle Genetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010293","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sanofi-Oncology"},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Karyopharm"},{"name":"Prothena"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.clml.2019.03.025","type":"journal-article","created":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T11:19:13Z","timestamp":1554117553000},"page":"255-263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Multiple Myeloma: Current Advances and Future Directions"],"prefix":"10.1016","volume":"19","author":[{"given":"Thomas","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol Ann","family":"Huff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2019.03.025_bib1","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.clml.2019.03.025_bib2","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.025_bib3","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/bloodadvances.2016002493","article-title":"Recent trends in multiple myeloma incidence and survival by age, race and ethnicity in the United States","volume":"1","author":"Costa","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2019.03.025_bib4","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.025_bib5","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/ejh.12829","article-title":"Association between complete response and outcomes in transplant-eligible myeloma patients in the era of novel agents","volume":"98","author":"van de Velde","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2019.03.025_bib6","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2019.03.025_bib7","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1200\/JCO.2013.54.8164","volume":"32","author":"Roussel","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.03.025_bib8","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.03.025_bib9","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2016-01-693580","article-title":"VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial","volume":"127","author":"Moreau","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.025_bib10","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.03.025_bib11","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","article-title":"Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma","volume":"123","author":"Martinez-Lopez","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.025_bib12","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2019.03.025_bib13","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1182\/blood-2014-07-590166","article-title":"Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction","volume":"125","author":"Rawstron","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.025_bib14","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"Gokbuget","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.025_bib17","doi-asserted-by":"crossref","first-page":"e346","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2019.03.025_bib18","first-page":"136","article-title":"ClonoSEQ cleared for residual cancer testing","volume":"8","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2019.03.025_bib19","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.clml.2019.03.025_bib20","doi-asserted-by":"crossref","first-page":"LBA-2","DOI":"10.1182\/blood-2018-120737","article-title":"Phase 3 randomized study of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in patients with newly diagnosed multiple myeloma (NDMM) ineligible for transplant (MAIA)","volume":"132","author":"Facon","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.025_bib21","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2017.35.15_suppl.8002","article-title":"An open-label, single arm, phase IIa study of bortezomib, lenalidomide, dexamethasone, and elotuzumab in newly diagnosed multiple myeloma","volume":"35","author":"Laubach","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2019.03.025_bib22","volume":"132","author":"Voorhees","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.025_bib23","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.03.025_bib24","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.025_bib25","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.18.00685","article-title":"Autologous transplantation, consolidation and maintenance therapy in multiple myeloma; Results of the BMT CTN 0702 trial","volume":"37","author":"Stadtmauer","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2019.03.025_bib26","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.03.025_bib27","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","article-title":"Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"36","author":"Siegel","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.03.025_bib28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomized, phase 3, open-label, multicenter study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2019.03.025_bib29","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomized phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2019.03.025_bib30","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.03.025_bib31","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1002\/cncr.31680","article-title":"Elotuzumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial","volume":"124","author":"Dimopoulos","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2019.03.025_bib32","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.03.025_bib33","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"15 suppl","key":"10.1016\/j.clml.2019.03.025_bib34","doi-asserted-by":"crossref","first-page":"8001","DOI":"10.1200\/JCO.2018.36.15_suppl.8001","article-title":"Pomalidomide (POM), bortezomib, and low-dose dexamethasone (PVd) vs bortezomib and low-dose dexamethasone (Vd) in lenalidomide (LEN)-exposed patients (pts) with relapsed or refractory multiple myeloma (RRMM): phase 3 OPTIMISMM trial","volume":"36","author":"Richardson","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.03.025_bib35","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S1470-2045(18)30354-1","article-title":"Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (ARROW): interim analysis of a randomized, phase 3 trial","volume":"19","author":"Moreau","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2019.03.025_bib36","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicenter, randomized, double-blind phase 3 trial","volume":"15","author":"San-Miguel","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2019.03.025_bib37","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1016\/S2352-3026(16)30147-8","article-title":"Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial","volume":"3","author":"San-Miguel","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2019.03.025_bib38","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1200\/JCO.2016.71.1663","article-title":"Systemic literature review and network meta-analysis of treatment outcomes in relapsed and\/or refractory multiple myeloma","volume":"35","author":"van Beurden-Tan","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.03.025_bib39","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.critrevonc.2017.03.018","article-title":"Triplet versus double combination regimens for the treatment of relapsed or refractory multiple myeloma: a meta-analysis of phase III randomized trials","volume":"113","author":"Sun","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clml.2019.03.025_bib40","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1182\/blood-2018-99-112697","article-title":"Three-year follow-up of the phase 3 Pollux study of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in relapsed or refractory multiple myeloma","volume":"132","author":"Bahlis","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.025_bib41","first-page":"3145","article-title":"Daratumumab, bortezomib and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): updated efficacy and safety analysis of Castor","volume":"130","author":"Spencer","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.025_bib42","doi-asserted-by":"crossref","first-page":"e554","DOI":"10.1038\/bcj.2017.31","article-title":"Carfilzomib, lenalidomide\u2013dexamethasone vs. lenalidomide\u2013dexamethasone in relapsed multiple myeloma by previous treatment","volume":"7","author":"Dimopoulos","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2019.03.025_bib43","doi-asserted-by":"crossref","first-page":"62435","DOI":"10.18632\/oncotarget.18722","article-title":"Meta-analysis of the efficacy of treatments for newly diagnosed and relapsed\/refractory multiple myeloma with del(17p)","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2019.03.025_bib44","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomized, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2019.03.025_bib45","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.025_bib46","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.03.025_bib47","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/s41375-018-0024-1","article-title":"Once-weekly carfilzomib, pomalidomide and low-dose dexamethasone for relapsed\/refractory myeloma: a phase I\/II study","volume":"32","author":"Bringhen","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.03.025_bib48","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood-2015-11-682518","article-title":"Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma","volume":"127","author":"Baz","year":"2016","journal-title":"Blood"},{"issue":"15 suppl","key":"10.1016\/j.clml.2019.03.025_bib49","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2018.36.15_suppl.8002","article-title":"Daratumumab (DARA) in combination with carfilzomib and dexamethasone (D-Kd) in lenalidomide (Len)-refractory patients with relapsed multiple myeloma (MM): subgroup analysis of MMY1001","volume":"36","author":"Chari","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.03.025_bib50","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/s41375-018-0038-8","article-title":"Phase I\/II trial of the oral regimen ixazomib, pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma","volume":"32","author":"Krishnan","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.03.025_bib51","doi-asserted-by":"crossref","first-page":"E17","DOI":"10.1002\/ajh.25327","article-title":"Carfilzomib weekly 20\/56 mg\/m2, lenalidomide and dexamethasone for early relapsed refractory multiple myeloma","volume":"94","author":"Richez","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2019.03.025_bib52","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41408-018-0104-5","article-title":"Bendamustine, pomalidomide and dexamethasone for relapsed and\/or refractory multiple myeloma","volume":"8","author":"Sivaraj","year":"2018","journal-title":"Blood Cancer J"},{"issue":"15 suppl","key":"10.1016\/j.clml.2019.03.025_bib53","doi-asserted-by":"crossref","first-page":"8019","DOI":"10.1200\/JCO.2018.36.15_suppl.8019","article-title":"Carfilzomib, bendamustine and dexamethasone (KBd) in advanced multiple myeloma: the EMN09-trial","volume":"36","author":"Gramatzki","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.03.025_bib54","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11; 14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.025_bib55","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1182\/blood-2017-06-788323","article-title":"Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed\/refractory MM","volume":"130","author":"Moreau","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.025_bib56","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1200\/JCO.2017.75.5207","article-title":"Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma","volume":"36","author":"Vogl","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.03.025_bib57","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-116663","article-title":"Results of the pivotal STORM study (part 2) in penta-refractory multiple myeloma (MM): deep and durable responses with oral selinexor plus low dose dexamethasone in patients with penta exposed and triple class-refractory MM","author":"Chari","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.025_bib58","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1182\/blood-2018-06-858852","article-title":"Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma","volume":"132","author":"Bahlis","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.025_bib59","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","article-title":"Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial","volume":"19","author":"Trudel","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2019.03.025_bib60","author":"Topp","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.025_bib61","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.6004\/jnccn.2017.7045","article-title":"Emerging role of CAR T-cells in non-Hodgkin\u2019s lymphoma","volume":"15","author":"Avanzi","year":"2017","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2019.03.025_bib62","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41416-018-0346-9","article-title":"Call-based immunotherapy approaches for multiple myeloma","volume":"120","author":"Kriegsmann","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2019.03.025_bib63","doi-asserted-by":"crossref","first-page":"8007","DOI":"10.1200\/JCO.2018.36.15_suppl.8007","article-title":"bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed\/refractory multiple myeloma: updated results from a multicenter phase 1 study","volume":"36","author":"Noopur","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.03.025_bib64","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A\u00a0phase I, open-label study of LCAR-38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clml.2019.03.025_bib65","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/bjh.15003","article-title":"Enumeration and characterization of circulating multiple myeloma cells in patients with plasma cell disorders","volume":"180","author":"Foulk","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2019.03.025_bib66","doi-asserted-by":"crossref","first-page":"e0181447","DOI":"10.1371\/journal.pone.0181447","article-title":"Prognostic value of circulating plasma cells in patients with multiple myeloma: a meta-analysis","volume":"12","author":"Li","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2019.03.025_bib67","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood-2012-01-405985","article-title":"Clonal competition with alternating dominance in multiple myeloma","volume":"120","author":"Keats","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.025_bib68","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","article-title":"Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy","volume":"25","author":"Lohr","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2019.03.025_bib69","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.clml.2019.03.025_bib70","doi-asserted-by":"crossref","first-page":"15086","DOI":"10.1038\/ncomms15086","article-title":"Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates","volume":"8","author":"Kis","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.clml.2019.03.025_bib71","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1182\/bloodadvances.2018025197","article-title":"Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow","volume":"2","author":"Mazzotti","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2019.03.025_bib72","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1053\/j.seminhematol.2018.02.008","article-title":"Mass spectrometry methods for detecting monoclonal immunoglobulins in multiple myeloma minimal residual disease","volume":"55","author":"Thoren","year":"2018","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clml.2019.03.025_bib73","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1373\/clinchem.2015.242651","article-title":"Clonotypic light chain peptides identified for monitoring minimal residual disease in multiple myeloma without bone marrow aspiration","volume":"62","author":"Bergen","year":"2016","journal-title":"Clin Chem"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019302538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019302538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:31:33Z","timestamp":1761870693000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265019302538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":71,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S2152265019302538"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.03.025","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiple Myeloma: Current Advances and Future Directions","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.03.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}